Peptides discussed in this review are subjects of ongoing scientific investigation and are not approved as pharmaceutical treatments in many jurisdictions
Over the next decade, several longer-acting versions were developed, including: Victoza (liraglutide) approved in 2010 Bydureon approved in 2012 Trulicity approved in 2014 During this period the medications were primarily prescribed for diabetes , and awareness outside medical circles was relatively limited
They were less likely to experience an overdose, drug-related hospitalization, drug-related death or suicide attempt
However, as with any injectable therapy, certain risks and considerations must be understood and appropriately managed
These injections replicate the glucagon-like peptide-1 (GLP-1) hormone
Global frequencies of clinically important HLA alleles and their implications for the cost-effectiveness of preemptive pharmacogenetic testing